NCT07871162|Not Yet RecruitingPhase 2
Fisetin for Improving Vascular Function in Older Adults: A Phase II Clinical Trial
Targeting Cellular Senescence With Fisetin for Improving Vascular Endothelial Function in Older Adults
Loading search results
Targeting Cellular Senescence With Fisetin for Improving Vascular Endothelial Function in Older Adults
Sponsor study identifier
Secondary identifiers
NIH
interventional
136
1 country
1
Study Start
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
March 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Aging is associated with the development of vascular dysfunction, which increases the risk for cardiovascular disease. This clinical trial will assess if supplementation with the natural compound fisetin can improve vascular endothelial function in older adults. The clinical trial will also assess if any effects of fisetin on endothelial function are associated with reduced cellular senescence. The study will also evaluate safety, tolerability and adherence with fisetin treatment.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 6, 2026
Actual (reported)October 13, 2026
Actual (reported)November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
June 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Change from baseline in endothelial function at 3 months
Brachial artery flow-mediated dilation
3 months
Change from baseline in suppression of endothelial function by mitochondrial oxidative stress at 3 months
3 months
Change from baseline in the effects of circulating factors on endothelial cell nitric oxide (NO) and total and mitochondrial reactive oxygen species (mitoROS) production at 3 months
3 months
Change from baseline in cerebrovascular function at 3 months
3 months
Fisetin will be administered in an intermittent manner with six three-day dosing periods at a dose of 2 mg/kg/day separated by two weeks.
Placebo capsules identical in appearance to fistin capsules will be administered in an intermittent manner with six three-day dosing periods separated by two weeks.
University of Colorado Boulder
Boulder, Colorado, 80309, United States
Matthew J Rossman, PhD
University of Colorado, Boulder
First Submitted
October 6, 2026
First Posted
October 13, 2026
Study Start
November 2026
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Primary Completion
COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
March 2031
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
June 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 15, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: